CLSN - Celsion Corporation

NasdaqCM - NasdaqCM Delayed price. Currency in USD
2.00
+0.06 (+3.09%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close1.94
Open1.91
Bid1.97 x 2000
Ask2.20 x 2000
Day's range1.90 - 2.04
52-week range0.19 - 6.06
Volume808,378
Avg. volume3,523,003
Market cap21.99M
Beta1.64
PE ratio (TTM)N/A
EPS (TTM)-5.58
Earnings date18 May 2017 - 19 May 2017
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.00
Trade prices are not sourced from all markets
  • Cancer Space Last Week Update: Pipeline Expansion in Focus
    Zackslast month

    Cancer Space Last Week Update: Pipeline Expansion in Focus

    Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.

  • Celsion's Immunotherapy Candidate Impresses, Stock Surges
    Zacks2 months ago

    Celsion's Immunotherapy Candidate Impresses, Stock Surges

    Celsion's (CLSN) pipeline candidate, GEN1, controls ovarian cancer in all patients in the phase Ib study and achieves a historical improvement in progression free survival.

  • We're sorry this is all we were able to find about this topic.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes